Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice

Biochemical and Biophysical Research Communications

Volumn 404, Issue 1, 2011, Pages 534-540

  Kawashima, Satoshi ^a   Matsuoka, Taka aki ^a   Kaneto, Hideaki ^a   Tochino, Yoshihiro ^a   Kato, Ken ^a   Yamamoto, Kaoru ^a   Yamamoto, Tsunehiko ^a   Matsuhisa, Munehide ^b   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Cell functions; Alogliptin; GLP 1 receptor; Insulin therapy; MafA; Piogli3tazone

Indexed keywords

ALOGLIPTIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; PIOGLITAZONE; TRANSCRIPTION FACTOR MAFA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL ISOLATION; CELL PROTECTION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; HEMOGLOBIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INSULIN RELEASE; INSULIN TREATMENT; MALE; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DEOXYGUANOSINE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MAF TRANSCRIPTION FACTORS, LARGE; MICE; MICE, INBRED C57BL; PIPERIDINES; RECEPTORS, GLUCAGON; THIAZOLIDINEDIONES; TRIGLYCERIDES; URACIL;

MUS;

EID: 78650866390     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.12.021     Document Type: Article

References (35)

1. Meier J.J. Beta cell mass in diabetes: a realistic therapeutic target?. Diabetlogia 2008, 51:703-713.
2. Kaneto H., Katakami N., Matsuhisa M., Matsuoka T.A. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm. 2010, 11. Article ID 453892.
3. Robertson R.P., Harmon J., Tran P.O.T., Pietout V. Beta cell glucose toxicity, lipotoxicity an dichronic oxidative stress in type 2 diabetes. Diabetes 2004, 53(Suppl. 1):S119-S124.
4. Bernardo L.W. β-Cell failure in diabetes and preservation by clinical treatment. Endocr. Rev. 2007, 28:187-218.
5. Ian W.C., Segundo M. β-Cell preservation with thiazolidinediones. Diabetes Res. Clin. Pract. 2006, 76:163-176.
6. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
7. Kawasaki F., Matsuda M., Kanda Y., Inoue H., Kaku K. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am. J. Physiol. Endocr. Metab. 2005, 288:E510-E518.
8. Kim H., Kim J., Kim S.H., Cha J.Y., Kim K.S., Ahn Y. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 2000, 49:1517-1524.
9. Kim H., Cha J.Y., Kim S.Y., Kim J., Rho K.J., Seong J.K., Lee N.T., Choi K.Y., Kim K.S., Ahn Y. Peroxisomal proliferator-activated receptor-γ upregulates glucokinase gene expression in β-cells. Diabetes 2002, 51:676-685.
10. Kim H., Ahn Y. Role of peroxisome proliferator-activated receptor-γ in the glucose-sensing apparatus of liver and β-cells. Diabetes 2004, 53:S60-S65.
11. Tamemoto H., Kadowaki T., Tobe K., Yagi T., Sakura H., Hayakawa T., Terauchi Y., Ueki K., Kaburagi Y., Satoh S., Sekihara H., Yoshioka S., Horikoshi H., Furuta Y., Ikawa Y., Kasuga M., Yazaki Y., Kasuga M., Aizawa S. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994, 372:182-186.
12. Kubota N., Tobe K., Terauchi Y., Eto K., Yamauchi T., Suzuki R., Tsubamoto Y., Komeda K., Nakano R., Miki H., Satoh S., Sekihara H., Sciacchitano S., Lesniak M., Aizawa S., Nagai R., Kimura S., Akanuma Y., Taylor S.I., Kadowaki T. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 2000, 49:880-1889.
13. Rizzo M., Rizvi A.A., Spinas G.A., Rini G.B., Berneis K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Exp. Opin. Pharmacother. 2009, 18:1495-1503.
14. Nauck M.A., Garber A., Vilsboll T., Madsbad S., Gallwitz B. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009, 32(Suppl. 2):S223-S231.
15. Doyle M.E., Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 2007, 113:546-593.
16. Olbrot M., Rud J., Moss L.G., Sharma A. Identification of beta-cell-specific insulin gene transcription factor RIPE3b1 as mammalian MafA. Proc. Natl. Acad. Sci. USA 2002, 99:6737-6742.
17. Kataoka K., Han S.I., Shioda S., Hirai M., Nishizawa M., Handa H. MafA is a glucose-regulated and pancreatic beta-cell-specific transcriptional activator for the insulin gene. J. Biol. Chem. 2002, 277:49903-49910.
18. Matsuoka T.A., Zhao L., Artner I., Jarrett H.W., Friedman D., Means A., Stein R. Members of the large Maf transcription family regulate insulin gene transcription in islet beta cells. Mol. Cell. Biol. 2003, 23:6049-6062.
19. Matsuoka T.A., Artner I., Henderson E., Means A., Sander M., Stein R. The MafA transcription factor appears to be responsible for tissue-specific expression of insulin. Proc. Natl. Acad. Sci. USA 2004, 101:2930-2933.
20. Zhang C., Moriguchi T., Kajihara M., Esaki R., Harada A., Shimohata H., Oishi H., Hamada M., Morito N., Hasegawa K., Kudo T., Engel J.D., Yamamoto M., Takahashi S. Maf A is a key regulator of glucose-stimulated insulin secretion. Mol. Cell. Biol. 2005, 25:4969-4976.
21. Sharma A., Olson L.K., Robertson R.P., Stein R. The reduction of insulin gene transcription in HIT-T15 beta cells chronically exposed to high glucose concentration in associated with the loss of RIPE3b1 and STF-1 transcription factor expression. Mol. Endcrinol. 1995, 9:1127-1134.
22. Poitout V., Olson L.K., Robertson R.P. Chronic exposure of βTC-6 cells to suprophysiologic concentrations of glucose decreases binding of the RIPE3b1 insulin gene transcription activator. J. Clin. Invest. 1996, 97:1041-1046.
23. Jonas J.C., Sharma A., Hasenkamp W., Iikova H., Patane G., Laybutt R., Bonner-Weir S., Weir G.C. Chronic hyperglycemia triggers loss of pancreatic β cell differentiation in an animal model of diabetes. J. Biol. Chem. 1996, 277:14112-14121.
24. Matsuoka T., Kajimoto Y., Watada H., Kaneto H., Kishimoto M., Umayahara Y., Fujitani Y., Kamada T., Kawamori R., Yamasaki Y. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J. Clin. Invest. 1997, 99:144-150.
25. Matsuoka T.A., Kaneto H., Miyatsuka T., Yamamoto T., Yamamoto Y., Kato K., Shimomura I., Stein R., Matsuhisa M. Regulation of MafA expression in pancreatic β-cell in db/db mice with diabetes. Diabetes 2010, 59:1709-1720.
26. Xu G., Kaneto H., Laybutt D.R., Duvivier-Kali V.F., Trivedi N., Suzuma K., King G.L., Weir G.C., Bonnoer-Weir S. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia. Diabetes 2007, 56:1551-1558.
27. Shu L., Matveyenko A.V., Kerr-Conte J., Cho J.H., McIntosh C.H.S., Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum. Mol. Genet. 2009, 18:2388-2399.
28. Wang H., Brun T., Kataoka K., Sharma A.J., Wollheim C.B. MAFA controls genes implicated in insulin biosynthesis and secretion. Diabetologia 2007, 50:348-358.
29. Waguri M., Yamamoto K., Miyagawa J.I., Tochino Y., Yamamori K., Kajimoto Y., Nakajima H., Watada H., Yoshiuchi I., Itoh N., Imagawa A., Namba M., Kuwajima M., Yamasaki Y., Hanafusa T., Matsuzawa Y. Demonstration of two different processes of beta-cell regeneration in a new diabetic mouse model induced by selective perfusion of alloxan. Diabetes 1997, 46:1281-1290.
30. Tousoulis D., Tsarpalis K., Cokkinos D., Stefanadis C. Effects of insulin resistance on endothelial function: possible mechanisms and clinical implications. Diabetes Obes. Metab. 2007, 10:834-842.
31. Jiang Z.Y., Lin Y.W., Clemont A., Feener E.P., Hein K.D., Igarashi M., Yamauchi T., White M.F., King G.L. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J. Clin. Invest. 1999, 104:447-457. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10449437.
32. Harmon J.S., Stein R., Robertson R.P. Oxidative stress-mediated, post-translational loss of MafA protein as a contributing mechanism to loss of insulin gene expression in glucotoxic beta cells. J. Biol. Chem. 2005, 280:11107-11113. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10449437.
33. Matsuoka T.A., Kaneto H., Stein R., Miyatsuka T., Kawamori D., Henderson E., Kojima I., Matsuhisa M., Hori M., Yamasaki Y. MafA regulates expression of genes important to islet beta-cell function. Mol. Endocrinol. 2007, 21:2764-2774. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10449437.
34. Artner I., Hang Y., Mazur M., Yamamoto T., Guo M., Lindner J., Magnuson M.A., Stein R. MafA and MafB regulate genes critical to beta-cells in a unique temporal manner. Diabetes. 2010, 59:2530-2539. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10449437.
35. Kulkarni R.N., Brüning J.C., Winnay J.N., Postic C., Magnuson M.A., Kahn C.R. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999, 96:329-339.